Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...

The CDC has rescheduled a key advisory committee meeting on vaccine experts to April following a delay in February, a week ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

The White House is reportedly considering former U.S. Rep. Michael Burgess (R-Texas) as its nominee to head the CDC. Burgess, ...

Discover insights from Autolus Therapeutics' Q4 2024 earnings call, featuring AUCATZYL's successful U.S. launch, strong financials, and pipeline updates.

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company’s ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

The latest analyst coverage could presage a bad day for BioNTech SE (NASDAQ:BNTX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little ...